PharmaResearch Co., Ltd. (KOSDAQ:214450)
South Korea · Delayed Price · Currency is KRW 289,000
+500 (0.17%)
Jun 12, 2026, 3:30 PM KST
PharmaResearch Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, PharmaResearch stock has a consensus rating of "Buy" and an average price target of ₩516,214. The average 1-year stock price forecast is 78.62% higher than the current stock price, while the lowest is ₩330,000 (+14.19%) and the highest is ₩717,000 (+148.10%).
Price Target: ₩516,214 (+78.62%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PharmaResearch stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 6 | 7 | 7 | 7 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 14 | 14 | 14 |
Financial Forecast
Revenue This Year
662.32B
from 536.29B
Increased by 23.50%
Revenue Next Year
796.37B
from 662.32B
Increased by 20.24%
EPS This Year
19.12K
from 14.93K
Increased by 28.05%
EPS Next Year
23.19K
from 19.12K
Increased by 21.28%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 692.3B | ||
| Avg | 662.3B | ||
| Low | 638.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 29.1% | ||
| Avg | 23.5% | ||
| Low | 19.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 21,579.00 | ||
| Avg | 19,121.03 | ||
| Low | 15,754.25 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 44.5% | ||
| Avg | 28.0% | ||
| Low | 5.5% |